KR20220122691A - 경도 외상성 뇌 손상의 치료 - Google Patents

경도 외상성 뇌 손상의 치료 Download PDF

Info

Publication number
KR20220122691A
KR20220122691A KR1020227025653A KR20227025653A KR20220122691A KR 20220122691 A KR20220122691 A KR 20220122691A KR 1020227025653 A KR1020227025653 A KR 1020227025653A KR 20227025653 A KR20227025653 A KR 20227025653A KR 20220122691 A KR20220122691 A KR 20220122691A
Authority
KR
South Korea
Prior art keywords
ghrelin
variant
mtbi
days
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227025653A
Other languages
English (en)
Korean (ko)
Inventor
비샬 반살
카르틱 샤
마이클 와이앤드
Original Assignee
옥세이아 바이오파마슈티칼스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 옥세이아 바이오파마슈티칼스, 인코포레이티드 filed Critical 옥세이아 바이오파마슈티칼스, 인코포레이티드
Publication of KR20220122691A publication Critical patent/KR20220122691A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227025653A 2019-12-23 2020-12-22 경도 외상성 뇌 손상의 치료 Withdrawn KR20220122691A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962953130P 2019-12-23 2019-12-23
US62/953,130 2019-12-23
PCT/US2020/066703 WO2021133844A1 (en) 2019-12-23 2020-12-22 Treatment of mild traumatic brain injury

Publications (1)

Publication Number Publication Date
KR20220122691A true KR20220122691A (ko) 2022-09-02

Family

ID=76575665

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227025653A Withdrawn KR20220122691A (ko) 2019-12-23 2020-12-22 경도 외상성 뇌 손상의 치료

Country Status (11)

Country Link
US (1) US20230031262A1 (cg-RX-API-DMAC10.html)
EP (1) EP4081238A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023508250A (cg-RX-API-DMAC10.html)
KR (1) KR20220122691A (cg-RX-API-DMAC10.html)
CN (1) CN114980915A (cg-RX-API-DMAC10.html)
AU (1) AU2020412765A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022012365A2 (cg-RX-API-DMAC10.html)
CA (1) CA3165738A1 (cg-RX-API-DMAC10.html)
IL (1) IL294156A (cg-RX-API-DMAC10.html)
MX (1) MX2022007844A (cg-RX-API-DMAC10.html)
WO (1) WO2021133844A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220370804A1 (en) * 2021-01-22 2022-11-24 The Regents Of The University Of Colorado, A Body Corporate Motor learning and vagus nerve stimulation (vns) paired with motor learning to treat demyelinating diseases, conditions and disorders
CN113723530B (zh) * 2021-09-02 2022-03-25 中国科学院自动化研究所 基于视频分析和电子心理沙盘的智能心理评估系统
US20260077018A1 (en) * 2022-09-07 2026-03-19 Oxeia Biopharmaceuticals, Inc. Treatment of mild traumatic brain injury

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6545697B2 (ja) * 2013-11-15 2019-07-17 ニューラル・アナリティクス・インコーポレーテッド 神経学的状態の診断のための脳の血流速度の構造的特徴をモニタリングすること
US9119832B2 (en) * 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
HK1231413A1 (zh) * 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
CA2961889A1 (en) * 2014-08-19 2016-02-25 Oxeia Biopharmaceuticals, Inc. Methods of treating mild brain injury
US20180028617A1 (en) * 2015-02-19 2018-02-01 The Regents Of The University Of California Methods of treating mild brain injury and post-traumatic stress disorder
WO2016144978A1 (en) * 2015-03-09 2016-09-15 Oxeia Biopharmaceuticals, Inc. Methods of treating cognitive impairments or dysfunction
WO2017075535A1 (en) * 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions

Also Published As

Publication number Publication date
MX2022007844A (es) 2022-09-07
US20230031262A1 (en) 2023-02-02
CN114980915A (zh) 2022-08-30
BR112022012365A2 (pt) 2022-08-30
JP2023508250A (ja) 2023-03-01
IL294156A (en) 2022-08-01
CA3165738A1 (en) 2021-07-01
AU2020412765A1 (en) 2022-07-14
WO2021133844A1 (en) 2021-07-01
EP4081238A1 (en) 2022-11-02
EP4081238A4 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
Obermann et al. Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial
Pittock et al. Eculizumab in aquaporin-4–positive neuromyelitis optica spectrum disorder
Busse et al. Liberty Asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma
Brown et al. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial
Warden et al. Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury
Ondo et al. Gabapentin for essential tremor: a multiple‐dose, double‐blind, placebo‐controlled trial
Stolz et al. Intensified therapy with inhaled corticosteroids and long-acting β2-agonists at the onset of upper respiratory tract infection to prevent chronic obstructive pulmonary disease exacerbations. A multicenter, randomized, double-blind, placebo-controlled trial
Feil et al. Safety and efficacy of acetyl-DL-leucine in certain types of cerebellar ataxia: the ALCAT randomized clinical crossover trial
Dart et al. The Efficacy of Antivenin Latrodectus (Black Widow) Equine Immune F (abʹ) 2 Versus Placebo in the Treatment of Latrodectism: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial
EP4081238A1 (en) Treatment of mild traumatic brain injury
Rose et al. Treatment for inclusion body myositis
Abelev et al. Medicinal cannabis for the treatment of chronic refractory pain: an investigation of the adverse event profile and health-related quality of life impact of an oral formulation
Tackenberg et al. Acetylcholine receptor antibody titers and clinical course after influenza vaccination in patients with myasthenia gravis: a double-blind randomized controlled trial (ProPATIent-Trial)
Becker et al. (-)-Phenserine and inhibiting pre-programmed cell death: in pursuit of a novel intervention for Alzheimer's disease
Buta et al. Real-world evidence of allergen immunotherapy
Cals et al. Dose timing and patient compliance with two antibiotic treatment regimens for lower respiratory tract infections in primary care
Attallah et al. Efficacy, safety and quality of life of oxybutynin versus aluminum chloride hexahydrate in treating primary palmar hyperhidrosis
US20260077018A1 (en) Treatment of mild traumatic brain injury
Nasser et al. Serotonin Syndrome Precipitated by Paxlovid Initiation
HK40080092A (en) Treatment of mild traumatic brain injury
Khokhar et al. Vaccination counseling with and without excipient skin testing in patients with suspected allergic reactions to mRNA COVID-19 vaccines and patients with atopy
Rodríguez-Prieto et al. Effectiveness of Transcranial Direct Current Stimulation for Migraine Treatment: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Pérez-Garrigues et al. Patient baseline characteristics in an open-label multinational study of betahistine in recurrent peripheral vestibular vertigo: the OSVaLD study
CN121175045A (zh) 用于治疗夏科-马里-图思病的组合物和方法
Yaeger et al. Ropivacaine intramuscular paracervical injections for pediatric headache: a randomized placebo-controlled trial

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203